Overview

A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

Status:
Not yet recruiting

Trial end date:
2025-03-31

Target enrollment:

Participant gender:

Summary

A clinical study to investigate the long-term safety and torelability of SEP-363856 in clinically stable adult patients with schizophrenia in Japan.

Phase:

Phase 3

Details

Lead Sponsor:

Sumitomo Pharma Co., Ltd.